Raffaele Colombo
@raffcolo
ADCs, targeted therapies, chemistry, biotech, pharma. Associate Director @ Zymeworks
🎉 It's an incredible honor and privilege to be named one of the 2024 PharmaVoice 100 by @PharmaVoice, alongside so many talented and inspiring leaders in the life sciences industry! 🎉 Check out the full list of this year #PharmaVoice100 honorees here: pharmavoice.com/news/pv100-pha…
Nerd alert! What do the latest proposed INNs tell us about $MGNX $AZN $BNTX $GSK $IVBXF and other ADCs? Via @ApexOnco -> oncologypipeline.com/apexonco/node/… H/t @raffcolo
Submit an abstract by July 21 for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26; Boston), chaired by Ryan B. Corcoran, Tim F. Greten, and Elena Garralda. Learn more: brnw.ch/21wUhRI #Targets25 @EORTC @theNCI
Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer @Annals_Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR gbr01.safelinks.protection.outlook.com/?url=https%3A%…
I didn't know dato-DXd was already approved in Russia for EGFR-mutant NSCLC patients... ...3 months ahead of the U.S.! Link: gxpnews.net/2025/03/astraz… (translation below in blue).
Dato-DXd now approved for patients with EGFR-mutated NSCLC after EGFR-directed & platinum-based therapies! Accelerated approval based on TROPION-Lung05 and TROPION-Lung01 ORR was 45% (95% CI: 35, 54) and median DOR was 6.5 months (95% CI: 4.2, 8.4)
In EGFR-m patients from TROPION-Lung05, no clear correlation with TROP2 expression. Maybe enriched in TROP2 QCS-NMR+?
🆕 FDA grants accelerated approval to Dato-DXd for EGFR-mutated NSCLC post-TKI + chemo 👏 But what’s the full picture? 🤔🧵 🔹 Based on 117 pts pooled from TROPION-Lung01 & Lung05 🔹 ORR: 43% | PFS: 5.8 mo | OS: 15.6 mo 📊 🔹 Prior osimertinib in 82% of pts 🔹 Common tox:…
Pooled analysis of EGFR-mutant NSCLC from TROPION-Lung05 and TROPION-Lung01 was presented at #ESMOASIA24:
Dato-DXd now approved for patients with EGFR-mutated NSCLC after EGFR-directed & platinum-based therapies! Accelerated approval based on TROPION-Lung05 and TROPION-Lung01 ORR was 45% (95% CI: 35, 54) and median DOR was 6.5 months (95% CI: 4.2, 8.4)
DB-1303/BNT323 (aka trastuzumab pamirtecan) is currently in phase 3 The trial names were very bold: "DYNASTY-Breast01" (DB-1303 vs T-DM1 in patients with HER2+ BC, NCT06265428) "DYNASTY-Breast02" (DB-1303 vs Investigator's Choice in patients with HER2-Low, HR+ BC, NCT06018337)
💊 P1003 is the same payload used in DB-1303/ BNT323. Most of the other Duality's ADCs use P1021 instead. P1003 was disclosed in INN list #131 (see: pamirtecan). P1021 is still undisclosed, but likely as below (from patents). All exatecan derivatives (DXd and Ed-04 as ref.)